BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone1-345-949-4123
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$198.22 million
Profitability
Miscellaneous
Employees2,070
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Beigene (NASDAQ:BGNE) Frequently Asked Questions
What is Beigene's stock symbol?
Beigene trades on the NASDAQ under the ticker symbol "BGNE."
How were Beigene's earnings last quarter?
Beigene Ltd (NASDAQ:BGNE) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($1.43) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($3.01) by $1.58. The business had revenue of $243.35 million for the quarter, compared to analyst estimates of $65.58 million. Beigene had a negative net margin of 153.32% and a negative return on equity of 38.41%. Beigene's revenue was up 360.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.92) earnings per share. View Beigene's Earnings History.
When is Beigene's next earnings date?
What price target have analysts set for BGNE?
8 analysts have issued twelve-month target prices for Beigene's stock. Their forecasts range from $170.00 to $201.00. On average, they anticipate Beigene's stock price to reach $185.00 in the next twelve months. This suggests a possible upside of 38.8% from the stock's current price. View Analyst Price Targets for Beigene.
What is the consensus analysts' recommendation for Beigene?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 1 sell rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beigene.
Has Beigene been receiving favorable news coverage?
Headlines about BGNE stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Beigene earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Beigene.
Who are some of Beigene's key competitors?
Some companies that are related to Beigene include Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), UCB (UCBJF), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), Bausch Health Companies (BHC) and Teva Pharmaceutical Industries (TEVA).
What other stocks do shareholders of Beigene own?
Who are Beigene's key executives?
Beigene's management team includes the folowing people:
- Mr. John V. Oyler, Co-Founder, CEO & Chairman (Age 51)
- Dr. Xiaodong Wang, Co-Founder, Chairman of the Scientific Advisory Board & Director (Age 56)
- Dr. Heng Liang, CFO & Chief Strategy Officer (Age 56)
- Dr. Jane E. Huang M.D., Chief Medical Officer - Hematology (Age 46)
- Dr. Xiaobin Wu, Pres & Gen. Mang. of China
When did Beigene IPO?
(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.
Who are Beigene's major shareholders?
Beigene's stock is owned by a number of of institutional and retail investors. Top institutional investors include Sumitomo Mitsui DS Asset Management Company Ltd (0.00%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang. View Institutional Ownership Trends for Beigene.
Which institutional investors are buying Beigene stock?
How do I buy shares of Beigene?
Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Beigene's stock price today?
One share of BGNE stock can currently be purchased for approximately $133.27.
How big of a company is Beigene?
Beigene has a market capitalization of $6.33 billion and generates $198.22 million in revenue each year. The company earns $-673,770,000.00 in net income (profit) each year or ($12.15) on an earnings per share basis. Beigene employs 2,070 workers across the globe.View Additional Information About Beigene.
What is Beigene's official website?
How can I contact Beigene?
Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]
MarketBeat Community Rating for Beigene (NASDAQ BGNE)
MarketBeat's community ratings are surveys of what our community members think about Beigene and other stocks. Vote "Outperform" if you believe BGNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
